Haorui Genomics pioneers the application of long-read sequencing in clinical molecular diagnostics, developing innovative IVD products and data platforms that bridge cutting-edge technology and patient care. We deliver tailored diagnostic solutions for transplantation, transfusion medicine, genetic disorders, and pharmacogenomics, supported by a complete suite of long-read sequencing platforms and a team of seasoned industry experts. Our end-to-end product and service ecosystem is designed to transform sequencing innovation into tangible clinical impact.
Our portfolio is anchored by AltruTypeTM, a pioneering long-read HLA genotyping assay engineered for seamless local deployment, and HemoSureTM, a comprehensive blood group genotyping solution. AltruTypeTM delivers high-resolution profiling across 14 clinically relevant HLA genes, while HemoSureTM provides exhaustive characterization of 22 red blood cell blood group systems and complete platelet (HPA) locus coverage. Complementing these core offerings, we have developed targeted assays for genetic disease testing and pharmacogenomics, meticulously tailored to address the nuanced requirements of diverse clinical workflows.
We partner with over 100 blood centers and hospitals worldwide, generating high-impact research that solves complex diagnostic challenges. Committed to setting industry standards, we are actively securing global patents and CE marks for our long-read sequencing-based assays, ensuring our products meet the highest standards of precision, compliance, and clinical utility.
微信二维码